Bibliography
- SULLENGER BA, GALLARDO HF, UNGERS GE, GILBOA E: Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell (1990) 63(3):601–608.
- MORISHITA R, GIBBONS GH, HORIUCHI M et al.: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Nati Acad. Sci. USA (1995) 92(13):5855–5859.
- ELLINGTON AD, SZOSTAK JVV: In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 346:818–822.
- TUERK C, GOLD L: Systematic evolutionof ligands by exponential enrichment: RNAligands to bacteriophage T4 DNA polymerase. Science (1990) 249:505–510.
- OSBORNE SE, ELLINGTON AD:Nucleic acid selection and the challenge of combinatorial chemistry. Chem. Rev (1997) 97(2):349–370.
- BRODY EN, GOLD L: Aptamers as therapeutic and diagnostic agents. J.Biotechnol. (2000) 74(1):5–13.
- WHITE RR, SULLENGER BA, RUSCONI CP: Developing aptamers into therapeutics. Clin. Invest. (2000) 106(8):929–934.
- GOLD L, POLISKY B, UHLENBECK 0, YARUS M: Diversity of oligonucleotide functions. Anna. Rev Biochem. (1995) 64:763–797.
- CHARLTON J, SENNELLO J, SMITH D: In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem. Biol. (1997) 4(11):809–816.
- GOLDEN MC, COLLINS BD, WILLIS MC, KOCH TH: Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. Biotechnol (2000) 81(3):167–178.
- WHITE R, RUSCONI C, SCARDINO E et al.: Generation of species crossreactive aptamers using 'toggle' SELEX. MM. Thec (2001) 4(6):567–573.
- WHITE RR, SHAN S, RUSCONI CP et al.: Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc. Nati Acad. Sci. USA (2003) 100(9):5028–5033.
- RUSCONI CP, YEH A, LYERLY HK, LAWSON JH, SULLENGER BA: Blocking the initiation of coagulation by RNAaptamers to Factor VIIa. Thromb. Haemost. (2000) 84:841–848.
- RUSCONI CP, SCARDINO E, LAYZERJ et al.: RNA aptamers as reversible antagonists of coagulation Factor IXa. Nature (2002) 419:90–94.
- EYETECH STUDY GROUP: Preclinical and Phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 22(2):143–152.
- TUCKER CE, CHEN LS, JUDKINS MB, FARMER JA, GILL SC, DROLET DW: Detection and plasma pharmacokinetics of an antivascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. Chromatogr: B. Biomed. Sci. Appl. (1999) 732:203–212.
- WATSON SR, CHANG YF, O'CONNELL D, WEIGAND L, RINGQUIST S, PARMA DH: Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev (2000) 10(2):63–75.
- BOCK LC: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 355:564–566.
- RUCKMAN J, GREEN LS, BEESON J et al.: 2 --Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascularendothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. (1998) 273(32):20556–20567.
- WU AM, CHEN W, RAUBITSCHEK A et al.: Tumour localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology (1996) 2(1):21–36.
- GOLD L: Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. (1995) 270:13581–13584.
- SANTULLI-MAROTTO S, NAIR SK, RUSCONI C, SULLENGER B, GILBOA E: Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumour immunity. Cancer Res. (2003) 63(21):7483–7489.
- DEANDA A JR, COUTRE SE, MOON MR et al: Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann. Thorac. Surg. (1994) 58(2):344–350.
- LIU X, CAO G, DING H et al.: Screening of functional antidotes of RNA aptamersagainst bovine thrombin. FEBS Lett. (2004) 562(1-3):125–128.
- FAMULOK M, MAYER G: Aptamers as tools in molecular biology and immunology. Carr. Top. Microbiol Immunol (1999) 243:123–136.
- GOLD L, ALPER J: Keeping pace with genomics through combinatorial chemistry. Nat. Biotechnol (1997) 15:297.
- EYETECH STUDY GROUP: Antivascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology (2003) 110(5) :979–986.